文献速递脊柱关节炎

银屑病关节炎与斑块状银屑病临床试验的全球招募模式与安慰剂应答率

Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis.
PubMed 文献 · Arthritis Rheumatol · 2025-09-23

该分析纳入银屑病关节炎51项试验(6843例患者,女性52%±5.7%)和斑块状银屑病43项试验(5671例患者,女性32%±7.1%),以人均国民总收入(GNI)为社会经济代理指标,发现GNI与安慰剂组主要终点应答率呈负相关。作者认为全球招募向欠富裕国家扩展可能提高安慰剂应答率。

要点

  • 银屑病关节炎试验中,GNI每增加1万国际元,安慰剂组ACR20应答率β=-5.7%(95%CI -7.8%至-3.5%,P<0.001)。
  • 斑块状银屑病试验中,GNI每增加1万国际元,安慰剂组PASI75应答率β=-1.1%(95%CI -2.0至-0.3,P=0.011)。
  • 作者认为全球招募向欠富裕国家扩展可能提高银屑病关节炎和斑块状银屑病研究的安慰剂应答率。

核心结论

  • 全球招募向欠富裕国家扩展可能提高银屑病关节炎和斑块状银屑病试验的安慰剂应答率,这些较高的安慰剂应答率可能反映这些国家感知获益较高,导致患者成功入组后出现均值回归。

研究设计与样本

  • 分析银屑病关节炎51项试验(6843例患者,女性52%±5.7%)和斑块状银屑病43项试验(5671例患者,女性32%±7.1%),研究生物制剂和靶向合成药物治疗。
  • 以按国家招募中心数加权的人均国民总收入(GNI)作为社会经济因素代理指标,采用线性混合模型分析全球招募模式与安慰剂组应答率的关系。

主要发现

  • 银屑病关节炎试验中,GNI与主要终点安慰剂应答率呈负相关(ACR20:β=-5.7%每1万国际元;95%CI -7.8%至-3.5%;P<0.001)。
  • 斑块状银屑病试验中,GNI与主要终点安慰剂应答率呈负相关(PASI75:β=-1.1%;95%CI -2.0至-0.3;P=0.011)。
  • 使用其他结局指标和替代经济指标(联合国人类发展指数和世界卫生组织自付医疗支出)的敏感性分析具有证实性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Placebo effects are a significant challenge in the conduct of clinical trials. We explored how global recruitment patterns influence the extent of placebo responses in randomized controlled trials of psoriatic arthritis and plaque psoriasis. METHODS: We conducted an analysis of 51 trials (6,843 patients; 52% ± 5.7% female) in psoriatic arthritis and 43 trials (5,671 patients; 32% ± 7.1% female) in plaque psoriasis investigating biologic and targeted synthetic therapeutics. We investigated to what extent global recruitment patterns are related to the extent of response rates in the placebo arms of these clinical trials by investigating underlying socioeconomic factors using the average per capita gross national income (GNI; weighted for recruiting study centers per country) as proxy of these patterns in linear mixed models. RESULTS: We identified a negative association of GNI and placebo response rates on the primary endpoints across psoriatic arthritis trials (American College of Rheumatology 20%: β = -5.7% per 10,000 international dollars; 95% confidence interval [CI] -7.8% to -3.5%; P < 0.001) and plaque psoriasis trials (Psoriasis Area and Severity Index 75%: β = -1.1%; 95% CI -2.0 to -0.3; P = 0.011). Sensitivity analyses using other outcome measures and alternative economic metrics, such as the United Nations Human Development Index and World Health Organization out-of-pocket health expenditures, were confirmatory. CONCLUSION: The global expansion of trial recruitment to less affluent countries may increase placebo rates in studies of psoriatic arthritis and plaque psoriasis. These higher placebo rates may reflect the higher perceived benefit in these countries, leading to regression to the mean after patients have been successfully enrolled.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kerschbaumer A, Steiner M, Khalili S, et al. Global Recruiting Patterns and Placebo Response Rates in Clinical Trials of Psoriatic Arthritis and Plaque Psoriasis. Arthritis Rheumatol. 2025. PMID: 40583519. doi:10.1002/art.43302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。